中国肺癌杂志2018，Vol.21Issue(5)：413-418,6.DOI:10.3779/j.issn.1009-3419.2018.05.10
中央型非小细胞肺癌立体定向放射治疗
Stereotactic Body Radiotherapy for Centrally Located Non-small Cell Lung Cancer
摘要
Abstract
A few study has proven that about 90% of local control rates might be benefit from stereotactic body radiotherapy (SBRT) for patients with medically inoperable stage I non-small cell lung cancer (NSCLC), it is reported SBRT associated overall survival and tumor specific survival is comparable with those treated with surgery. SBRT has been accepted as the first line treatment for inoperable patients with peripheral located stage I NSCLC. However, the role of SBRT in centrally located lesions is controversial for potential toxic effects from the adjacent anatomical structure. This paper will review the definition, indication, dose regimens, dose-volume constraints for organs at risk, radiation technology, treatment side effect of centrally located NSCLC treated with SBRT and stereotactic body proton therapy.关键词
立体定向放射治疗/中央型/肺肿瘤Key words
Stereotactic body radiotherapy/Centrally/Lung neoplasms引用本文复制引用
万于茗,黄婧..中央型非小细胞肺癌立体定向放射治疗[J].中国肺癌杂志,2018,21(5):413-418,6.基金项目
本文受国家自然科学基金(No.81573024)项目资助This study was supported by grants from the National Natural Science Foundation of China (to Feng XU)(No.81573024). （No.81573024）
